FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Responses	s)														
1. Name and Address of Reporting Person * Niihara Yutaka					2. Issuer Name and Ticker or Trading Symbol Emmaus Life Sciences, Inc. [EMMA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner				
(Last) (First) (Middle) 21250 HAWTHORNE BLVD., SUITE 800					3. Date of Earliest Transaction (Month/Day/Year) 02/10/2020						X Officer (give title below) Other (specify below) Chairman and CEO					
(Street)				4. I	4. If Amendment, Date Original Filed(Month/Day/Year)					_X_ Form fil	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person					
TORRANCE, CA 90503										Form file						
(City)	(State)	(Zip)		,	Гable I - N	Non-I	Derivative	Secur	ities A	cquired, Disp	osed of, or I	Benefici	ially Own	ed	
(Instr. 3)		2. Transaction Date (Month/Day/Yea	r) any		3. Transaction Code (Instr. 8)		(Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D	p Indirect Benefic Owners	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	V	Amount	(A) or (D)	Price				or Indirection (I) (Instr. 4)	t (mstr. 4	•)
Common value	stock, \$0.	001 par	02/10/2020			P		9,200	A	\$ 1.71 (1)	10,315,892	3		D (2)		
Common value	stock, \$0.	001 par	02/11/2020			P		17,500	A	\$ 1.84 (3)	10,333,39	3		D (2)		
Common value	stock, \$0.	001 par	02/12/2020			P		4,400	A	\$ 1.86 (4)	10,337,792	3		D (2)		
Common stock, \$0.001 par value										92,794			I	By Ho International Hospid Inc. (5	ational ce,	
Common stock, \$0.001 par value										63,000			I	By So Niihar		
Reminder:	Report on a s	separate line	for each class of	securities	beneficially	owned dir	Pe	ersons w	ho re	s form	to the collectory are not requiremently valid	uired to res	pond	unless	SEC 147	74 (9-02)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
Security	Conversion	3. Transaction Date Exercise ice of erivative Securities A. Deemed Execution Date, if Month/Day/Year) 3. Transaction Date Execution Date, if Code (Instr. 8) 5. Number and Expi (Month/Day/Year) 6. Date Fand Expi (Month/Day/Year		nd Expirat	Expiration Date An Unth/Day/Year) An Se		Reporte		tive ties F cially I I S ving I ted ciction(s)	form of Derivative ecurity: Direct (D) r Indirect	11. Naturo of Indirect Beneficial Ownershi (Instr. 4)					
					Code V	(A) (I	Е	ate xercisable		ration	Amount or Number of Shares					

Reporting Owners

Relationships

Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Niihara Yutaka 21250 HAWTHORNE BLVD. SUITE 800 TORRANCE, CA 90503	X	X	Chairman and CEO	

Signatures

Yutaka Niihara, M.D., M.P.H.	02/12/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.70 to \$1.73, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1), in footnote (3) and in footnote (4) to this Form 4.
- (2) The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife.
- (3) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.77 to \$1.89, inclusive.
- (4) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.75 to \$1.90, inclusive.
- (5) Hope International Hospice, Inc, is a California corporation of which Dr. Niihara and his wife are the sole shareholders and directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.